Advanced phase III trials for both injectable and oral VK2735, with strong efficacy and safety data supporting further development. R&D expenses and net loss increased due to expanded clinical activity, but a robust cash position supports ongoing programs and infrastructure growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.